Madrigal Pharmaceuticals, Inc.

NASDAQ:MDGL

242.25 (USD) • At close September 19, 2024
Bedrijfsnaam Madrigal Pharmaceuticals, Inc.
Symbool MDGL
Munteenheid USD
Prijs 242.25
Beurswaarde 5,259,901,575
Dividendpercentage 0%
52-weken bereik 119.76 - 299.98
Industrie Biotechnology
Sector Healthcare
CEO Mr. William J. Sibold
Website https://www.madrigalpharma.com

An error occurred while fetching data.

Over Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic

Vergelijkbare Aandelen

Atrion Corporation logo

Atrion Corporation

ATRI

459.92 USD

Cronos Group Inc. logo

Cronos Group Inc.

CRON

2.23 USD

Outset Medical, Inc. logo

Outset Medical, Inc.

OM

0.594 USD

RadNet, Inc. logo

RadNet, Inc.

RDNT

69.64 USD

Revolution Medicines, Inc. logo

Revolution Medicines, Inc.

RVMD

46.18 USD

Agios Pharmaceuticals, Inc. logo

Agios Pharmaceuticals, Inc.

AGIO

47.38 USD

NGM Biopharmaceuticals, Inc. logo

NGM Biopharmaceuticals, Inc.

NGM

1.54 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)